Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants

Pharmacogenetics

Volumn 9, Issue 1, 1999, Pages 17-23

  Cravchik, Anibal ^a,c   Sibley, David R ^b   Gejman, Pablo V ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c National Institute for Alcohol Abuse and Alcoholism   (United States)

Author keywords

Dopamine; Neuroleptics; Potency; Schizophrenia

Indexed keywords

ALANINE; CHLORPROMAZINE; CLOZAPINE; CYSTEINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; PROLINE; RECEPTOR PROTEIN; RISPERIDONE; SERINE; THIORIDAZINE; TIOTIXENE; VALINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0032891646     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199902000-00003     Document Type: Article

References (26)

1. Asghari V, Schools O, van Kats S, Ohara K, Jovanovic V, Guan HC, et al. Mol Pharmacol 1994; 46:364-373.
2. Cheng YC, Prusoff WH. Biochem Pharmacol 1973; 22:3099-3108.
3. Cichon S. Nothen MM, Catalano M, Di Bella D, Maier W, Lichtermann D, et al. Psychiatr Genet 1995; 5:97-103.
4. Civelli O, Bunzow JR, Grandy DK. Annu Rev Pharmacol Toxicol 1993; 33:281-307.
5. Cravchik A, Sibley DR, Gejman PV. J Biol Chem 1996; 271:26013-26017.
6. Gaddum JH. Pharmacol Rev 1957; 9:211-218.
7. Gejman PV, Ram A, Gelernter J, Friedman E, Cao Q, Pickar D, et al. Jama 1994; 271:204-208.
8. Gershon ES, Badner JA, Goldin LR, Sanders AR, Cravchik A, Detera-Wadleigh SD. Neuropsychopharmacology 1998; 18:233-242.
9. Goldman D, Urbanek M, Guenther D, Robin R, Long JC. Am J Med Genet 1997; 74:386-394.
10. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham M, et al. Proc Natl J Acad Sci U S A 1989; 86:9762-9766.
11. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M. Biochem Biophys Res Commun 1993; 196:1369-1375.
12. Kaplan HI, Sadock BJ, Grebb JA. Synopsis of psychiatry. 7th edn. Baltimore: Williams and Wilkins; 1994.
13. Lannfelt L, Sokoloff P, Martes MP, Pilon C, Giros B, Jonsson E, et al. Psychiatr Genet 1992; 2:249-256.
14. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ. Hum Mol Genet 1993; 2:767-773.
15. Lazareno S, Birdsall NJM. Br J Pharmacol 1993a; 109:1110-1119.
16. Lazareno S, Birdsall NJM. Trends Pharmacol Sci 1993b; 14:237-239.
17. Naylor L, Woodward R, Daniell S, Coley C, Strange P. Biochem Soc Trans 1995; 23:87-91.
18. Nothen MM, Cichon S, Hemmer S, Hebebrand J, Remschmidt H, Lehmkuhl G, et al. Hum Mol Genet 1994; 3:2207-2212.
19. Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y. Br J Psychiatry 1991; 158:850-853.
20. Pohjalainen T, Cravchik A, Gejman PV, Rinne J, Nagren K, Syvalahti E, Hietala J. Biochem Biophys Res Commun 1997; 232:143-146.
21. Ram A, Cao Q, Keck PE Jr, Pope HG Jr, Otani K, Addonizio G, et al. Am J Med Genet 1995; 60:228-230.
22. Richardson MA, Haugland G, Craig TJ. Am J Psychiatry 1991; 148:1322-1328.
23. Sibley DR, Monsma FJ. Trends Pharmacol Sci 1992; 13:61-69.
24. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D. Science 1974; 184:1243-1253.
25. Sobell JL, Lind TJ, Sigurdson DC, Zald DH, Snitz BE, Grove WM, et al. Hum Mol Genet 1995; 4:507-514.
26. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Mol Psychiatry 1997; 2:139-145.